INMD Stock Forecast: InMode Ltd. Price Predictions for 2026-2027
The 5 Wall Street analysts covering InMode Ltd. hold a median 12-month price target of $15 — +20.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 85 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores InMode Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
INMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on INMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +20.8% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | Baird | Maintains | Neutral | $17 → $15 |
| 7 May 2026 | Baird | Maintains | Neutral | $17 → $14 |
| 7 May 2026 | Barclays | Maintains | Overweight | $21 → $19 |
| 17 Dec 2025 | Canaccord Genuity | Maintains | Hold | — |
| 6 Nov 2025 | UBS | Maintains | Neutral | — |
| 10 Oct 2025 | Canaccord Genuity | Maintains | Hold | — |
| 10 Oct 2025 | Needham | Reiterates | Hold | — |
| 30 July 2025 | Barclays | Maintains | Overweight | — |
| 30 July 2025 | Needham | Reiterates | Hold | — |
| 11 July 2025 | Canaccord Genuity | Maintains | Hold | — |
| 30 Apr 2025 | Barclays | Maintains | Overweight | — |
| 29 Apr 2025 | BTIG | Downgrade | Neutral | — |
| 29 Apr 2025 | Canaccord Genuity | Maintains | Hold | — |
| 29 Apr 2025 | UBS | Maintains | Neutral | — |
| 28 Apr 2025 | Needham | Reiterates | Hold | — |
| 14 Apr 2025 | Jefferies | Maintains | Hold | — |
| 14 Apr 2025 | Needham | Reiterates | Hold | — |
| 9 Apr 2025 | Needham | Reiterates | Hold | — |
| 5 Feb 2025 | Barclays | Maintains | Overweight | — |
| 4 Feb 2025 | Needham | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for INMD.
This page is one stock. Monday covers all of them.
INMD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
INMD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, InMode Ltd. returned −9.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
INMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 10.6×
- Price / sales
- 1.9×
- Price / book
- 1.1×
- EV / EBITDA
- 3.3×
Cheaper than 71% of US stocks
Cheaper than 49% of US stocks
Cheaper than 67% of US stocks
Cheaper than 87% of US stocks
- Revenue growth (YoY)
- −1.1%
- Earnings growth (YoY)
- −13.7%
- Gross margin
- 74.8%
- Operating margin
- 18.0%
- Net margin
- 19.9%
Higher than 27% of US stocks
Higher than 23% of US stocks
Higher than 87% of US stocks
Higher than 76% of US stocks
Higher than 81% of US stocks
- Return on equity
- 11.4%
- Return on assets
- 5.7%
- Dividend yield
- —
Higher than 66% of US stocks
Higher than 79% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
InMode Ltd. has a market value of $730.8M and an enterprise value of $222.0M.
Revenue in the twelve months to 30 June 2026: $374.6M. The latest quarter shrank 0.0% year on year.
Net income over the same four quarters: $77.5M, a 20.7% net margin.
Diluted earnings per share, trailing twelve months: $1.23.
Free cash flow in the twelve months to 30 June 2026: $82.5M.
InMode Ltd. spent $87.8M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 10.6×; forward P/E: 9.3× — the forward figure prices analyst consensus estimates, not reported earnings.
InMode Ltd. employs 660 people — $568K of revenue per employee.
Data provided by Twelve Data
INMD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at INMD’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own InMode Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about INMD
What is the INMD stock price forecast for 2026-2027?
The 5 Wall Street analysts covering InMode Ltd. have a median 12-month price target of $15, with estimates ranging from $14 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is INMD stock a buy right now?
Of the 5 analysts covering InMode Ltd., 0 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InMode Ltd. 85 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank INMD?
As at 21 Nov 2026, InMode Ltd. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
Will INMD stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +20.8% from the last close, and Ticker Nerd's factor model ranks InMode Ltd. 85 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the INMD stock forecast for 2030?
No analyst covering InMode Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $15 over the next 12 months.
How has INMD stock performed over the past year?
InMode Ltd. returned -9.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does InMode Ltd. do?
InMode Ltd. is a medical technology company that develops, manufactures, and markets minimally invasive and non-invasive aesthetic treatment systems. Its current product portfolio is built around radio frequency-based platforms used in body and face contouring, skin tightening, fat reduction, skin rejuvenation, and women’s health procedures.
About InMode Ltd.
InMode Ltd. is a medical technology company that develops, manufactures, and markets minimally invasive and non-invasive aesthetic treatment systems. Its current product portfolio is built around radio frequency-based platforms used in body and face contouring, skin tightening, fat reduction, skin rejuvenation, and women’s health procedures. The company also offers solutions for dermatology, plastic surgery, gynecology, otolaryngology, and ophthalmology, reflecting a broad focus across medical aesthetics and specialty care. InMode serves hospitals, clinics, and medical practices through a global distribution network, with commercial activity across the United States, Europe, Asia, and other international markets. Headquartered in Yokneam, Israel, InMode Ltd. is recognized for energy-based devices that support office-based procedures and expand treatment options in the growing aesthetic medicine market.
CEO Mr. Moshe Mizrahy · 660 employees · Israel · https://www.inmodemd.com